1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 Nov 2021
Admin
News Article

Union Therapeutics Receives Fda Fast Track Designation For Oral Orismilast For The Treatment Of Moderate To Severe Atopic Dermatitis

Fda'S Fast Track Designation For Oral Orismilast Underscores The Urgent Need For New Treatment Option With Potential To Fulfil The Unmet Medical Needs For People Affected By Atopic Dermatitis (Ad)Ad Is The Most Common Chronic Inflammatory Skin Disease In The Developed WorldOrismilast Is A Next Generation Pde4 Inhibitor With Broad Anti-Inflammatory Properties Also In Development For The Treatment Of Psoriasis And Hidradenitis Suppurativa (Hs)Union Therapeutics A/S, A Privately-Held, Multi-Asset, Clinical Stage, Pharmaceutical Company Focused On Immunology And Infectious Diseases, Today Announced That The Us Food And Drug Administration (Fda) Has Granted Fast Track Designation To Oral Orismilast For The Treatment Of Moderate To Severe Ad. The Fda'S Fast Track Designation Is Intended To Facilitate The Development And Review Of Drug Candidates That Treat Serious Conditions And Address An Unmet Medical Need. A Drug Candidate That Receives Fast Track Designation Is Eligible For More Frequent Interaction With The Fda To Discuss The Drug Candidate'S Development Plan As Well As Eligibility For Rolling Review And Priority Review.Kim Kj

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!